Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.
Alessandra Fabi(Agostino Gemelli University Polyclinic), F. Cognetti(Sapienza University of Rome), I Sacchi(Cancer Institute (WIA)), Umberto Pacetti(Tumori Foundation), Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), Maria Simona Pino(Massachusetts General Hospital), C. Nardoni(Cancer Institute (WIA)), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Paolo Carlini(National Cancer Institute)
PubMed
September 9, 2004
Cited by 8
Related Papers
The Chromosomal Instability Pathway in Colon Cancer
|Gastroenterology|2010|932
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
|Annals of Oncology|2016|398
Bortezomib Sensitizes Pancreatic Cancer Cells to Endoplasmic Reticulum Stress-Mediated Apoptosis
|Cancer Research|2005|307